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Abstract
Lung transplantation is the method of choice for the treatment of end-stage
pulmonary diseases. A limited donor supply has dramatically increased the waiting
time for transplant recipients. Approximately 4000 patients are currently on the
transplant waiting list. Unfortunately, up to 10-20% of these patients will die
from their underlying lung disease before an organ becomes available. Currently,
only 10-20% of cadaveric donor organs offered for transplantation are judged to
be acceptable under the current selection criteria. Of the donor lungs selected for
transplantation, 15-30% of them fail due to primary graft dysfunction (PGD). PGD
is a severe allograft ischemia-reperfusion (I/R) injury syndrome occurring in the
hours following transplantation. It significantly affects morbidity as well as early
and late mortality. This has resulted in an intense pressure to search for alternative
selection criteria for selecting suitable donor lungs. In this study, we attempt to
further our understanding of the gene products involved in PGD by observing the
changes in gene expression across donor lungs that developed PGD versus those
that did not. Our second goal is to use a machine learning technique - support
vector machine, to distinguish donor lungs suitable for transplantation versus those
that are not, based on the gene expression data. Results from microarray analysis
produced a set of differentially expressed transcripts that were involved in signalling
and apoptosis pathways. Various transcripts particular to stress-sensitive pathways
were also identified. Results also indicate that the metallothionein gene, specifically
metallothionein 3, may protect donor lungs from developing PGD. A classification
accuracy of 70% was achieved, when a set of 100 differentially expressed transcripts
was used to differentiate unsuitable donor lungs from suitable ones. This is the first
such attempt to combine the identification of a molecular signature for PGD, using
human samples, with machine learning methods for class (donor lung) prediction.

Introduction

a major shortage of donor organs and the incidence of primary graft dysfunction (PGD).
PGD is a severe allograft ischemia-reperfusion
(I/R) injury syndrome occurring in the hours
following transplantation. It significantly af-

Lung transplantation has gained widespread
acceptance for the treatment of end-stage pulmonary diseases. However, two significant
problems in clinical lung transplantation are
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and current donor selection criteria have shown
no correlation with the occurrence of PGD in
most cases [13, 14, 15, 16, 17].
A limited donor supply has dramatically
increased the waiting time for transplant recipients. Approximately 4,000 patients are currently on the transplant waiting list and this
has resulted in intense pressure to search for
alternative strategies. Unfortunately, up to
10-20% of these patients on the waiting list
will die from their underlying lung disease before an organ becomes available. Currently,
only 10-20% of cadaveric donor organs offered
for transplantation are judged to be acceptable
under the current selection criteria [18]. More
biologically meaningful donor selection criteria
may result in significant expansion of the number of lungs accepted from this potential donor
pool [5].
The results of the above mentioned studies suggest that there may be complex, occult biological factors present in donor lungs
which contribute to the development of PGD
that are not detected by the current donor organ evaluation. Gene expression profiling is
a powerful, high-performance tool of molecular biology that allows the analysis of the
levels of expression of thousands of genes simultaneously. It has been previously used to
study some transcripts involved in I/R using
a rat model, but the study did not differentiate the suitable lungs from the unsuitable [19].
Therefore, this is the first report, according to
our knowledge, where gene expression profiling
has been used on human samples, along with
the application of machine learning techniques
to automatically distinguish unsuitable donor
lungs from suitable donor lungs.
Our objective is two fold - the first is to
obtain a set of genes involved in PGD and
identify new gene products relevant to allograft
transplantation; and the second is to use this
set of genes for classification of donor lungs
into PGD positive (i.e. lungs that develop
PGD) or PGD negative (i.e. lungs that do not
develop PGD) categories. The first objective
would provide greater insights into the mechanism of PGD as well as extend the work of [19].

fects morbidity as well as early and late mortality. Improvements in operative techniques,
donor management, and immunosuppressive
protocols have decreased perioperative mortality to below 10% at most experienced lung
transplant centers [1, 2]. The one- and fiveyear survival rates have improved to 76% and
49%, respectively [1]. These results, however,
continue to lag behind those achieved for other
solid organ transplants. The occurrence of
PGD after lung transplantation significantly
increases the duration of mechanical ventilation, hospital length of stay and short-term
mortality after lung transplantation [3]. Survivors of PGD have a significantly protracted
recovery with impaired physical function up to
one year after transplantation and an increased
risk of death extending beyond the first year
after transplantation [3, 4].
The current criteria used to evaluate potential donor lungs appear to be inadequate
at predicting how these lungs will function
post-transplantation [5, 6, 7]. Donor organs
are evaluated for lung transplantation on the
basis of criteria that are primarily historically founded and largely arbitrary [8]. Relatively crude measures of lung function such
as chest radiography, arterial oxygen tension
on blood gases, and bronchoscopy are currently used to assess the quality of potential donor lungs. That these tools are inadequate in evaluating organs from prospective
donors is evidenced by two recent developments. First, the liberalisation of the selection criteria and the use of ‘marginal’ donor
lungs by many centers have not had a negative impact on outcome after transplantation
[9, 10, 11]. A recent study showed no significant difference in a number of indices for infection and inflammation between donor lungs
that were accepted and rejected for transplantation [7]. Second, the incidence of PGD or
I/R injury, after transplantation remains unchanged at 10-20% despite the increased use of
marginal donor lungs and improvements in all
areas of lung transplantation [2, 4, 12]. The
use of marginal donor lungs, extended graft
cold ischemic times, recipient pathophysiology
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[20, 21]. The authors of [22] have shown that
Wnt signalling, cell cycle, and apoptosis pathways play important roles in lung development.
We also have noticed an increased presence of
genes in these pathways in our study (Figure
2).
Next, we analysed the 42 downregulated
transcripts using IPA, and obtained 11 focus
genes. The network created from these 11
genes is shown in Figure 3.
Network 2 shows a lot of activity around
β-5 integrin (ITGB5) and GRB2-associated
binding protein 2 (GAB2). The focus genes
are shown in green coloured shapes and further
description of these nodes are given in Table
5. Figure 4 shows the location of the different gene products and the canonical pathways
present in Network 2. The legend for the network is shown in Figure 7.
Again, we observe similar pathways, as
the ones present in Network 1, in Network 2.
This is to be expected because a pathway can
consist of up and downregulated genes.
Both the networks show the presence of
nuclear factor-κB (NF-κB), stress-activated
protein kinases /N H2 -terminal Jun kinase
(SAPK/JNK) and p38 mitogen-activated protein kinase (MAPK) signalling pathways. NFκB plays a vital role in mediating immune
and inflammatory responses, and apoptosis.
It regulates the expression of a large number of genes. Many of the gene products
regulated by NF-κB in turn activate NFκB, such as vascular endothelial growth factor (VEGF), and receptor for advanced glycation end product (RAGE). Activation of
NF-κB involves the phosphorylation-induced,
proteasome-mediated degradation of the inhibitory subunit - inhibitory protein κB. This
protein is phosphorylated by an upstream serine kinase, which, in turn is phosphorylated
and activated by additional upstream serine
kinases. SAPK/JNK are members of the superfamily of MAP serine/threonine protein kinases. This family also includes p38 MAP kinases (p38 MAPK) and extracellular signalrelated kinases (ERK) [23]. JNK/SAPK and
p38 MAPK are known as stress-activated ki-

The set of genes identified as being involved
in PGD can be designated as the ‘molecular
signature’ of PGD. As many donor lungs that
may be actually good are discarded by the current selection criteria employed by physicians,
it would be useful to classify unseen donor
lungs, using the molecular signature coupled
with machine learning techniques, thereby increasing the possibility of having more available lungs for transplantation. This is the motivation behind our second objective.

Results and Discussion
The characteristics of the donor lungs are depicted in Table 1. The operative factors and
the characteristics of the patients who have
been identified with PGD versus those that
have not, are shown in Table 2 and Table 3,
respectively.

Pathways and gene products involved
in PGD
First, the upregulated transcripts were analysed using the Ingenuity Pathway Analysis
(IPA) software. There were 23 upregulated
transcripts, of which 13 were focus genes. Focus genes are the genes that map onto the Ingenuity Pathways Knowledge Base (IPKB). The
network generated from these genes are shown
in Figure 1.
Network 1 primarily centres around tumor protein p53 (TP53). The focus genes are
shown in red coloured shapes and more details on these nodes are given in Table 4. Figure 2 shows the location of the different gene
products and the canonical pathways present
in Network 1. The legend for the network is
shown in Figure 7.
It is natural to expect many pathways related to apoptosis and cell signalling as over
50% of the donor lungs (PGD positive and
PGD negative) were involved in some kind of
trauma. Interestingly, a few transcripts identified are also cancer related genes. There is
growing evidence of genetic parallels between
lung development and several types of cancer
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Table 1: Clinical donor characteristics
Characteristics
Age (years)
PaO2 (mm Hg)
Smoking history (pack-years)
Gender
Cause of death
Chest X-ray (CXR)

PGD (n=7)
26.6 ± 8.9
406.7 ± 80.5
1.5 ± 2.07
71% M, 29% F
57% Trauma, 43% NonTr
57% Abnl, 43% Nl

No PGD (n=24)
24.0 ± 9.8
449.7 ± 80.0
2.9 ± 6.32
83% M, 17% F
75% Trauma, 25% NonTr
33% Abnl, 66% Nl

p value
0.53
0.17
0.59
0.78
0.66
0.52

Table 2: Operative factors
Factors
Recipient Diagnosis
First lung ischemic time (min)
Second lung ischemic time (min)
Cardiopulmonary bypass (CPB)

PGD (n=7)
28.5% COPD, 28.5% CF, 43% Other
208 ± 44
330 ± 72
72%

No PGD (n=24)
33% COPD, 33% CF, 33% Other
240 ± 51
321 ± 51
17%

p value
0.98
0.18
0.69
0.02

Table 3: Outcomes of the patients with PGD and without PGD
Outcome
Days on ventilator
ICU stay (days)
Total length of stay (days)
Perioperative Mortality

PGD (n=7)
9.7 ± 11.7
11.3 ± 12.6
20.3 ± 13
28.5%

No PGD (n=24)
2.0 ± 3.7
2.9 ± 3.6
13.4 ± 8.1
0%

p value
0.01
0.006
0.09
0.02

Figure 1: Network 1 - upregulated genes in PGD. This network primarily centres around tumor protein p53
(TP53). The focus genes are shown in red coloured shapes. Further details on the focus genes are provided
in Table 4. The legend for this figure is Figure 7
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Figure 2: Network 1 with the canonical pathways overlaid. The focus genes are shown in red coloured
shapes. The location of the different gene products are also depicted. Further details on the focus genes are
provided in Table 4. The legend for this figure is Figure 7
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Table 4: Description of the upregulated transcripts from our DE list present in Network 1
Symbol

Gene Name

Canonical Pathways

TP53

tumor protein p53

Apoptosis Signalling, Cell Cycle: G1/S
Checkpoint Regulation, Cell Cycle:
G2/M DNA Damage Checkpoint
Regulation, Hypoxia Signalling in the
Cardiovascular System, PI3K/AKT
Signalling, SAPK/JNK Signalling,
Wnt/β-catenin Signalling

IFI16

γ-interferon
inducible
protein
16

unknown

TRIO

triple
functional
domain
(PTPRF
interacting)
cystic
fibrosis
transmembrane
conductance regulator, ATP-binding
cassette

unknown

LMNB1
SOS1

lamin B1
son
of
sevenless
homolog
1
(Drosophila)

DONSON

downstream neighbor of SON
solute carrier family 27 (fatty acid
transporter)
ring finger protein
19
neuropilin 2

unknown
B Cell Receptor Signalling, EGF
Signalling, ERK/MAPK Signalling,
Estrogen Receptor Signalling, FGF
Signalling, IGF-1 Signalling, IL-2
Signalling, IL-4 Signalling, IL-6 Signalling, Insulin Receptor Signalling,
Integrin Signalling, Natural Killer
Cell Signalling, Neuregulin Signalling,
Neurotrophin/Trk Signalling, PDGF
Signalling,
PI3K/AKT Signalling,
PPAR Signalling, PTEN Signalling,
SAPK/JNK Signalling, T Cell Receptor Signalling, TGF-&beta; Signalling,
VEGF Signalling
unknown

CFTR

SLC27A2

RNF19
NRP2

unknown

Role in Cell and diseases associated with
apoptosis, growth, cell cycle progression, cell death, proliferation, G1 phase,
transformation, senescence, G2 phase,
quantity Disease: cancer, neoplasia, tumorigenesis, lymphoid cancer,
lung cancer, head and neck cancer,
breast cancer, brain cancer, squamouscell carcinoma, metastasis, skin cancer,
lymphomagenesis, Li-Fraumeni syndrome, liver cancer, hyperplasia, lung
neoplasm, breast carcinoma, brain neoplasm, non-small cell lung cancer, dysplasia, etc.
differentiation, apoptosis, proliferation,
cell cycle progression, contact growth
inhibition, morphology, accumulation,
DNA damage response, G1/S phase
transition, senescence
invasiveness, transformation, tumorigenicity, morphology, reorganisation
binding, communication, whole-cell
conductance, quantity, regulatory volume decrease, size, acidification, formation Disease: hepatic system disorder,
inflammation, HIV infection, cystic fibrosis
apoptosis, disassembly, formation
transformation, growth, proliferation,
morphology, invasion, ruffling, breakdown, maturation, reorganization, differentiation Disease: tumorigenesis,
infection

unknown

Fatty acid metabolism

unknown

unknown

biogenesis, cell death, quantity

unknown

chemorepulsion, fasciculation, penetration, guidance, development, collapse,
innervation, defasciculation. Disease:
hemorrhage
binding, quantity, phagocytosis, engulfment, apoptosis, uptake, depletion
Disease: tangier disease, atherosclerosis, microhemorrhage, cerebral amyloid angiopathy, hemorrhage, coronary artery disease, membranoproliferative glomerulonephritis, primary hypoalphalipoproteinemia
unknown
cell death, damage, inhibition, proliferation, growth Disease: limbic seizure,
hypoxia, breast cancer

ABCA1

ATP-binding cassette, sub-family A
(ABC1)

unknown

XPO7
MT3

exportin 7
metallothionein
3
(growth
inhibitory
factor
(neurotrophic))

unknown
unknown
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Figure 3: Network 2 - downregulated genes in PGD. This network shows a lot of activity around β-5 integrin (ITGB5) and GRB2-associated binding protein 2 (GAB2). The focus genes are shown in green coloured
shapes. Further details on the focus genes are provided in Table 5. The legend for this figure is Figure 7

Figure 4: Network 2 with the canonical pathways overlaid. The focus genes are shown in green coloured
shapes. The location of the different gene products are also depicted. Further details on the focus genes are
provided in Table 5. The legend for this figure is Figure 7
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Table 5: Description of the downregulated transcripts from our DE list present in Network 2
Symbol

Gene Name

Canonical Pathways

ITGB5

β-5 integrin

Integrin Signalling

GAB2

GRB2-associated
binding protein 2

B Cell Receptor Signalling, PI3K/AKT
Signalling

STAM binding protein
BTG3 associated
nuclear protein
procollagenproline,
2oxoglutarate
4-dioxygenase (proline 4-hydroxylase),
alpha polypeptide I
ribosomal protein,
large, P2
HRAS-like suppressor 3
ribosomal protein
L36a

unknown

STAMBP
BANP
P4HA1

RPLP2
HRASLS3
RPL36A

unknown

Role in Cell and diseases associated with
binding, migration, adhesion, invasion,
cell spreading, internalization, killing,
cell death, outgrowth, anoikis Disease: tumorigenesis, melanoma, acute
myeloid leukemia, glioblastoma multiforme, prostatic carcinoma
proliferation, growth, differentiation,
degranulation, phagocytosis, survival,
adhesion, size, quantity, apoptosis Disease: systemic anaphylaxis, passive cutaneous anaphylaxis
apoptosis, cytostasis, proliferation, survival, cell death
cell cycle progression

Arginine and Proline Metabolism

unknown

unknown

unknown

unknown

colony formation, apoptosis, proliferation Disease: tumorigenesis
unknown

unknown

Control (MAQC) project [25], it is better to focus on pathways and broad functional relationships, rather than on individual genes. They
state that ‘even under the best circumstances,
gene lists will still differ somewhat from person to person and place to place’. In our work,
we have observed a good deal of overlap in the
functional categories / pathways of the identified transcripts. As not all animal model studies translate well into human analysis, our investigation takes the study performed by [19]
a step further by performing the analysis on
human samples and showing consensus.
An exciting observation was that the metallothionein family of gene products was identified as being upregulated in both studies. We
use the results from [19] and one can observe
the expression level of metallothionein in microarray and RT-PCR in Figure 5. As can be
seen, the levels of expression are much lower in
microarray. However, RT-PCR confirms that
it does have an increased expression. Hence,
the rat study as well as ours do confirm the
elevated expression of metallothionein.

nases, and are responsive to numerous exogenous and endogenous stress-inducing stimuli,
such as reactive oxygen species (ROS), oxidative stress, osmotic stress, proinflammatory cytokines, heat shock, and ultraviolet irradiation.
Oxidative stress is defined as a persistent imbalance between the production of highly reactive molecular species (primarily oxygen and
nitrogen) and antioxidant defences, finally resulting in tissue damage. There is evidence
in literature that NF-κB, SAPK/JNK and p38
MAPK signalling pathways are stress-sensitive
intracellular signalling systems, activation of
which results in the increased expression of numerous gene products that cause cellular damage [24].
Gene products associated with stressactivated pathways emerged from both our
study as well as the study in the rat model for
ischemia-reperfusion injury [19]. As the experimental protocol, and animal model are different, one would not expect too much of an overlap. As suggested by the recent articles in Nature Biotechnology by the MicroArray Quality
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Figure 5: Metallothionein expression in microarray vs. RT-PCR in the rat study [19]. The level
of expression of metallothionein is increased when verified by RT-PCR. This confirms that metallothionein does get upregulated.
tance of NF-κB in immune and inflammatory
responses pathways. There is also an indirect relationship between MT3 and epidermal
growth factor (EGF). EGF is involved in EGF
signalling, ephrin receptor signalling, neuregulin signalling, and NF-κB signalling. EGF’s
role in the cell is proliferation, migration, mitogenesis, apoptosis, growth, chemotaxis, transformation, stimulation, S phase, and differentiation. All this information on MT3 indicates
that it is a valuable gene associated with PGD
and needs to be analysed in more detail. The
overexpression of metallothionein may protect
the lung graft from PGD. We feel that this
is one of the most important insights into the
mechanism of PGD.

In order to further study metallothionein,
we extracted the metallotheionein 3 (MT3)
pathway from Network 1. The MT3 pathway
is shown in Figure 6.
Though the exact function of MT3 is not
well known, there are a few studies that have
explained the possible roles of metallothionein.
A recent study has shown that metallothioneins have positive effects during the early
phase of islet transplantation [26]. Another
study has shown that the metallothionein gene
is upregulated in wound margins particularly
in regions of high mitotic activity [27]. These
observations reflect its role in promoting cell
proliferation and reepithelialiation. Furthermore, selected growth factors may modulate
metallothionein gene expression and hence, the
ability of cells to proliferate [27]. As can be
seen from Figure 6, MT3 is connected to NFκB1. In human fibroblasts, NF-κB protein
consisting of p50 [NFKB1] and of p65 v-rel
reticuloendotheliosis viral oncogene homolog A
(RELA) increases expression of human MT3
mRNA. We already have discussed the impor-

Classification of donor lungs using
SVM
The set of 100 ranked transcripts, obtained
using RankGene, was used for the classification of donor lungs into PGD positive and
PGD negative classes by SVM. The classifica-
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Figure 6: Network 3 - Metallothionein pathway. In human fibroblasts, NF-κB protein consisting
of p50 [NFKB1] and of p65 v-rel reticuloendotheliosis viral oncogene homolog A (RELA) increases
expression of human MT3 mRNA. The overexpression of metallothionein may protect the lung
graft from PGD. The legend for this figure is Figure 7
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(a)

(b)

(c)
Figure 7: Network Legend (a)Key for nodes in the network, (b)Key for edges in the network, (c)Key for
edge labels in the network
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rate and possibly larger set of DE transcript
involved in PGD, as well as improved classification results.
As the differences at the macroscopic
level between PGD positive and PGD negative donor lungs are minimised after employing the clinical selection criteria, gene expression profiling would help in emphasising whatever small differences there may be. SVMs are
capable of using these marginal differences to
identify suitable and unsuitable donor lungs.
This is where machine learning plays a valuable role - assisting physicians and not necessarily overruling them. Hence, machine learning methods, such as SVMs, can be used in
conjunction with clinical criteria to identify
unsuitable donor lungs, thereby further decreasing the chances of using donor lungs that
would develop PGD.

tion accuracy of SVM in differentiating the two
classes was 70%. This indicates that this set
of transcripts does play a vital role in distinguishing unsuitable and suitable donor lungs.
The SVM did better at identifying the
suitable lungs (i.e. low false negative). Considering that the motivation behind using machine learning for the selection of suitable
donor lungs was to detect those that otherwise
would have been discarded, this observation is
promising. The unsuitable donor lungs were
more often misclassified and this can be attributed to the fact that there were very few
unsuitable donor lungs in the dataset (16 unsuitable lungs versus 34 suitable lungs) and
subsequently, an even smaller number in the
training set. Furthermore, our dataset had
been pre-selected by physicians based on clinical criteria. Hence, the dataset did not have
truly unsuitable donor lungs, i.e., lungs considered unsuitable by clinical criteria. Obviously,
certain lungs that passed the selection criteria,
developed PGD. In essence, these were lungs
that seemed to be good by the current clinical criteria. Hence, the gene expression patterns of the unsuitable donor lungs are very
similar to the patterns of suitable lungs. In
fact, when the gene expression values of the
DE transcripts were compared between PGD
positive and PGD negative lungs, the difference was marginal. These observations are not
surprising as both sets of lungs were considered suitable by clinical criteria, and therefore the difference between them would be very
minimal. After all, the lung transplant centre
at Washington University, Saint Louis, is the
largest in the world and also considered as one
of the best in the United States of America.
The SVM had difficulty in recognising
some unsuitable donor lungs as it was not being trained on the gene expression pattern of
a large number of unsuitable donor lungs, or,
for that matter, on a large number of truly unsuitable donor lungs. Given the fact that we
had only 50 samples, in which we did not have
truly unsuitable lungs, the classification performance is good. Increasing the sample size
in both categories would lead to a more accu-

Conclusion
The incorporation of biological information
into donor lung evaluation, based on studies
such as this one, may deem many of the excluded organs as suitable for transplantation,
directly impacting the mortality of patients on
the lung transplant waiting list. Studies show
that 15-30% of patients develop clinically significant primary graft dysfunction (PGD) after
lung transplantation. PGD is the single most
significant factor in determining perioperative
morbidity and mortality and has a devastating
impact on outcome following lung transplantation. It is the primary factor determining duration of mechanical ventilatory support and
length of ICU and hospital stay following lung
transplantation. Perioperative mortality rates
for those with clinically significant PGD are as
high as 40-60%. One year survival rates fall
from 69% to 40% and 2-year rates from 66%
to 27% in those who suffer significant PGD.
Furthermore, those that survive complications
of PGD endure lengthy hospitalisation periods
and a protracted and often compromised recovery, evidenced by inferior exercise tolerance
and pulmonary function testing and the inabil-
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ity to achieve independent lifestyles. Moreover, PGD is now being identified as a risk
factor for acute and chronic rejection.
In this study, gene expression profiling of
donor lung samples was used to determine gene
products that are associated with the development of PGD after transplantation. It also
resulted in analysing possibly relevant pathways involved in PGD. When biological markers were used to differentiate between PGD
positive and PGD negative lungs, a good classification accuracy was achieved. The incorporation of biological markers into donor organ evaluation will have a significant impact
on outcomes after lung transplantation, by potentially expanding the donor pool of organs
selected for transplantation and by identifying
lungs at risk for the development of PGD posttransplant, which would allow pre-treatment
of these high risk organs or matching of these
organs to relatively lower risk recipients. Further identification and elucidation of genetic
markers in donor lungs associated with PGD
could have a significant impact on lowering the
incidence and preventing the morbidity and
mortality of PGD after lung transplantation.
Our results indicate that we have successfully
achieved both our objectives.

informed consent before entrance into this research
protocol.

RNA Isolation
Single isolates of donor lung samples were homogenised in the presence of RNAzolB and finally
dissolved in RNase-free H2O. 25 g of total RNA was
treated with DNase using the Qiagen RNase-free
DNase kit and samples were further purified using RNeasy spin columns (Qiagen, Valencia, CA).
Total RNA treated with DNase was dissolved in
RNase-free H2O to a final concentration of 0.2 g/ l.
RNA quality was assessed by 1% agarose gel electrophoresis in the presence of ethidium bromide.
Samples that did not reveal intact and approximately equal 18S and 28S ribosomal bands were
excluded from further study.

cDNA Synthesis and Gene Expression
Profiling
This study used commercially available highdensity microarrays (Affymetrix, Santa Clara, CA)
that produce gene expression levels on 22,278 probe
sets (Affymetrix Human Genome U133Av2.0 Array). Each donor lung biopsy was analysed on a
different GeneChip. Preparation of cDNA, hybridisation, and scanning of the arrays were performed
according to the manufacturer’s instructions. The
arrays were scanned using the Affymetrix GeneArray scanner. Image analysis was performed with
the Affymetrix GeneChip software. We also performed a quality control test on the dataset and
results indicated that the dataset quality was good.

Materials and Methods
Donor Lung Sampling
From August 2003 to January 2005, biopsies of
50 donor lungs used for bilateral sequential lung
transplantation at Washington University School
of Medicine were obtained from the anterior right
middle lobe or lingula immediately prior to coldflushing and these samples were immediately snapfrozen in liquid nitrogen and then stored in a 70 Celsius freezer until used for analysis. Specimens were sampled using standard techniques for
open lung wedge biopsy. An area of lung tissue
approximately 1 x 1 cm was isolated and excised
using 2 staple lines from a 30 mm EndoGIA stapler (US Surgical, Norwalk, CT). This protocol was
approved by the Human Studies Committee and Institutional Review Board at Washington University
School of Medicine and protection of human subjects, namely recipients, was afforded by detailed

Data
The data from all 50 gene chips was normalised using the GCRMA method developed by [28]. The
50 donor lung samples were divided into two groups
- those that developed PGD after transplantation
(PGD positive) and those that did not (PGD negative). PGD was defined as T0 Grade III dysfunction according to International Society for Heart
and Lung Transplantation criteria - that is, a ratio of partial pressure of arterial oxygen (P aO2 ) to
fraction of inspired oxygen (F iO2 ) less than 200
on the first arterial blood gas in the intensive care
unit after transplantation (generally 4-6 hours after
actual reperfusion) [29]. Sixteen samples were classified as PGD positive according to this definition
and the remaining thirty-four were PGD negative.
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Transcripts Selection

were used for further analysis in Ingenuity Pathway Analysis software.

As data quality is important, we calculated
the quality of our dataset using the R package
‘affyQCReport’ [30] and results were favourable.
We then proceeded to the next step in our study
- the identification of differentially expressed (DE)
transcripts. The objective was to find a set of DE
transcripts/probes that could be used as a molecular signature for the condition. DE transcript extraction falls into two broad categories - wrapper
methods and filter methods. In wrapper transcript
selection methods, the DE transcript identification
phase is integrated with the classification phase. In
filter methods, the DE transcript extraction phase
is independent of the classification phase. In this
study, we used two packages for the identification
of DE transcripts - RankGene [31], and significance
analysis of microarrays (SAM) [32].
RankGene is a programme for analysing gene
expression data, feature selection and ranking
genes based on the predictive power of each
gene/transcript to classify samples into functional
or disease categories. It supports eight different
measures for quantifying a gene’s ability to distinguish between classes. For our analysis, we used
the t-statistics measure of predictability. SAM is
an open-source software which identifies DE genes
based on the change in gene expression relative to
the standard deviation of repeated measurements
[32]. It uses the false discovery rate (FDR) and
q-value method presented in [33] to select genes.
The q-value is analogous to the p-value and is corrected, through a permutation process, for the natural variability of the expression data. The q-value
of a transcript is the FDR for the transcript list
that includes that transcript and all transcripts
that are more significant. SAM also provides a tail
strength (TS) value which measures the deviation
of each p-value from its expected value. Therefore,
large positive TS values indicate evidence against
the null hypothesis, i.e., there are more small pvalues than one would expect by chance [34].
We first ran RankGene on the complete set of
probes. Since we were interested in the most highly
DE transcripts, we chose to take the top 100 transcripts from the ranked list for further analysis. On
this list of 100 DE transcripts, we applied SAM.
SAM output 81 up and down regulated transcripts
based on a FDR of 0% and a TS of 92.7%. After averaging the values of and removing multiple probes
matching to the same gene name, 23 upregulated
and 42 downregulated transcripts were obtained.
These sets of up and down regulated transcripts

Pathway analysis
Ingenuity Pathway Analysis (IPA) (www.ingenuity.com)
was used to perform pathway analysis on the two
sets of DE transcripts - upregulated and downregulated, to identify networks of genes that are
known to interact functionally. IPA uses the Ingenuity Pathways Knowledge Base(IPKB) which
contains large amounts of indivually modelled relationships between objects (e.g., genes, proteins
and mRNAs) to dynamically generate significant
biological/gene expression networks and pathways.
The identified DE transcripts from our analysis
that are mapped onto the IPKB are called ‘focus
genes’. These are used as starting points for building the networks. First, IPA queries the IPKB for
interactions between the focus genes and all other
genes stored in IPKB and then generates a set of
networks/pathways with a maximum of 35 genes.
A p value for each network is calculated according
to the user’s list of DE genes. This is accomplished
by comparing the number of focus genes that are
present in a given pathway, relative to the total
number of occurrences of those genes in all pathways stored in IPKB. The score of the network is
shown as the negative logarithm of the p value,
indicating the likelihood of the focus genes in a
network being found together by random chance.
In our study, we further analysed networks that
had a network score of 10 or higher. This network
analysis is an exploratory in silico approach and
does not necessarily indicate that the pathway or
network actually exists.

Support Vector Machines
Originally developed by Vapnik [35], the support
vector machine (SVM) is a statistical learning tool
which has been extensively used for binary classification with great success. Ranging from classification of cancer [36] to determination of haemodialysis dosage [37], SVMs have proven to be an effective
tool in a wide-range of applications.
SVM was used for the classification of patient
samples into PGD positive or PGD negative categories. The dataset consisted of 50 patient samples and 100 transcripts (ranked transcripts from
RankGene). Following is the manner in which SVM
was used. The dataset is divided into training and
test(unseen by the classifier) sets. The test set is
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129:1421–1429, 2005.

also the validation set because although the user
knows the classes of the samples in the test set,
the classifier does not see the samples in the test
set while it is training. The SVM is trained on
the training set. The classifier performance is measured by the prediction accuracy on the test set.
It is quite well known that the set of significant
genes (SG) from a particular set of training data
is very often very different from one chosen from
a different set of training data. Obtaining a SG
set from the complete dataset (i.e. from all 50 patient samples), leads to a selection bias. In order
to avoid selection bias, an external cross-validation
(CV) was performed i.e. the classifier performance
was measured using only the set of genes (i.e. a
subset of the 100 transcripts) obtained from the
training set and not from the complete dataset of
50 patients. Ten fold CV was carried out rather
than leave-one-out (LOO) CV as the variability in
the list of SG is much lower with 10 fold CV and
this is what is preferred.

[3] JD Christie, JS Sager, SE Kimmel,
VN Ahya, C Gaughan, NP Blumenthal,
and RM Kotloff. Impact of primary graft
failure on outcomes following lung transplantation. Chest, 127:161–165, 2005.
[4] JD Christie, RM Kotloff, VN Ahya,
G Tino, A Pochettino, C Gaughan, E DeMissie, and SE Kimmel. The effect of primary graft dysfunction on survival after
lung transplantation. Am J Respir Crit
Care Med, 171:1312–1316, 2005.
[5] AJ Fisher, JH Dark, and PA Corris. Improving donor lung evaluation: a new
approach to increase organ supply for
lung transplantation. Thorax, 53:818–820,
1998.
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